{
    "nct_id": "NCT04288089",
    "official_title": "An Open-Label Multicenter Phase 1b Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive HER2-Negative Breast Cancer",
    "inclusion_criteria": "1. ER+ HER2- locally advanced, recurrent, or metastatic breast cancer, as per local laboratory\n2. Prior therapy in the advanced/metastatic setting\n3. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n4. Has adequate bone marrow and organ function\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Uncontrolled significant active infections\n2. Major surgery or other locoregional treatment within 4 weeks before the 1st dose of study drug\n3. Inability to take oral medication or presence of malabsorption\n4. Active cardiac disease or a history of cardiac dysfunction\n5. Evidence of ongoing Alcohol or Drug Abuse",
    "miscellaneous_criteria": ""
}